







32	16/EE/0370	198596	MesoTRAP: A feasibility study comparing video-assisted thoracoscopic partial pleurectomy/decortication with indwelling pleural catheter in patients with trapped lung and pleural effusion due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.	No		16/12/2016	05/05/2017	11/01/2017	05/05/2017	09/05/2017	15/09/2017									Sponsor delayed confirmation of study open to recruitment at site	Sponsor
33	17/LO/0718	213056	PREvention of Cerebral Ischaemia in Stent treatment for carotid artery stenosis - A randomised trial of optimised antiplatelet therapy with outcome assessment on MRI (PRECISE-MRI)	No		11/04/2017	09/08/2017	24/07/2017	10/10/2017	20/10/2017								Y		Contracting delays with Sponsor, and Sponsor delay in provision of equipment	Sponsor
34	17/YH/0262	219133	TRITON: A randomised, placebo controlled trial to determine the efficacy and mode of action of ondansetron in the treatment of irritable bowel syndrome with diarrhoea	No		20/07/2017	15/12/2017	07/11/2017	14/03/2018	21/12/2017									Y	Sponsor delayed confirmation of study open to recruitment at site	Sponsor
35	16/EE/0234	194284	Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.	No		15/06/2016	25/05/2017	12/09/2016	25/05/2017	25/05/2017	19/07/2017							Y		Sponsor delay in site initiation. Eligible patients seen chose not to participate in study.	Sponsor
36	17/LO/1236	225042	Determining the predictive utility of short-term variation (STV) of fetal heart rate (FHR) for fetal acidemia, and the feasibility of using this for decision making in high-risk women during labour	Yes	17/01/2018	29/06/2017	22/08/2017	19/07/2017	19/12/2017	19/12/2017	19/12/2017								Y	Contracting delays with device manufacturer	Neither
37	17/YH/0179	226816	Developing and Testing a Clinical Grade Magnetic Impedance Spectroscopy Device for Cervical Assessment to Predict Preterm Birth	No		11/05/2017	05/09/2017	20/09/2017	18/10/2017	18/10/2017	18/10/2017	Y							Y	Relevant permissions delayed and not granted in time. Planned and agreed later start.	Sponsor
38	17/NW/0236	196147	Support, Positioning and Organ Stabilisation during Breast Cancer Radiation Therapy: The SuPPORT 4 All bra.	Yes	30/10/2017	03/05/2017	11/07/2017	18/05/2017	26/07/2017	03/08/2017	10/10/2017								Y	Sponsor delayed confirmation of study open to recruitment at site	Sponsor
39	17/YH/0146	157987	A Study Investigating Whether Vitamin and Mineral Supplementation Enhances Cognitive Outcome in Mild to Moderate Brain Injury, Compared to a Control Group	No		10/05/2017	17/07/2017	17/07/2017	07/08/2017	07/08/2017	18/09/2017								Y	Sponsor delay in provision of placebo and delayed confirmation of study open to recruitment at site	Sponsor
40	16/WS/0165	190574	ADSCaN: A randomised Phase II study of accelerated, dose escalated, sequential chemo-radiotherapy in non-small cell lung cancer	Yes	16/10/2017	15/03/2017	29/05/2017	13/02/2017	09/08/2017	16/08/2017	22/08/2017								Y	Contracting delays with Sponsor	Sponsor
41	17/YH/0083	220358	A randomised controlled trial of routine massage with a new lotion for the enhancement of skin health and cognitive development in infants	No		01/02/2017	08/06/2017	08/06/2017	15/06/2017	19/06/2017									Y	Planned and agreed later start date due to intrinsic study design	Sponsor



50	17/EM/0155	206803	Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of poniesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) - POINT	Yes	31/10/2017	05/05/2017	11/07/2017	10/07/2017	17/07/2017	27/07/2017	17/10/2017										Sponsor delayed confirmation of study open to recruitment at site.	Sponsor		
51	17/LO/0243	219613	A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis. (GLIMMER: GSK2330672 trial of Ibat inhibition with Multidose Measurement for Evaluation of Response)	Yes	04/09/2017	09/03/2017	12/05/2017	27/03/2017	12/05/2017	23/05/2017	04/08/2017											NHS provider staff availability	NHS Provider	
52	17/LO/0380	218003	A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of Crenezumab in patients with prodromal to mild Alzheimer's disease - Cread 2	No		05/01/2017	29/06/2017	18/05/2017	29/06/2017	29/06/2017	31/07/2017											Sponsor delayed confirmation of study open to recruitment at site.	Sponsor	
53	17/YH/0249	225721	Optimising Behavioural Observation Audiometry (BOA) in Adults with Learning Disabilities	No	26/02/2018	05/07/2017	14/11/2017	14/11/2017	16/11/2017	16/11/2017	16/11/2017									Y		Equipment required calibration by manufacturer which was delayed	Neither	
54	16/EM/0181	201126	TAMARIN: Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms	No		25/01/2017	16/06/2017	02/06/2016	04/05/2017	28/09/2017	28/09/2017												NHS Provider staff availability	NHS Provider
55	17/EE/0205	224373	A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma	Yes	12/02/2018	25/04/2017	05/10/2017	25/07/2018	06/10/2017	17/10/2017	03/11/2017										Y		Patients screened but no eligible patients identified. Also rare disease	Neither
56	17/LO/0525	221541	A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing efficacy and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03% / timolol 0.5% Ophthalmic Solution) in subjects with elevated intraocular pressure (MERCURY 3)	Yes	17/10/2017	06/02/2017	04/07/2017	30/06/2017	01/06/2017	06/07/2017	28/09/2017												Sponsor delayed confirmation of study open to recruitment at site	Sponsor
57	17/NW/0162	220300	HER2CLIMB – Phase 2 randomised, double-blinded, controlled study of Tucatinib vs placebo in combination with Capecitabine and Trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer	Yes	24/01/2018	02/02/2017	10/10/2017	11/05/2017	11/10/2017	13/10/2017	19/10/2017												No patients seen, strict patient eligibility criteria.	Neither
58	16/EM/0443	208418	STEM – A multicentre Phase 2 study of SFX-01 treatment and evaluation in patients with Estrogen Receptor (ER) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative metastatic breast cancer progressing on either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant	No		06/02/2017	17/07/2017	15/12/2016	01/08/2017	04/08/2017	25/08/2017												No eligible patients seen, strict patient eligibility criteria.	Neither



